Capricor Therapeutics, Inc. (NASDAQ:CAPR) Sees Volatile Trading – Down $0.19


Capricor Therapeutics, Inc. (NASDAQ:CAPR) is at $2.06 seeing a daily low of $1.91 and high of $2.48. This difference between the high and low distinguishes the stock as one of the most volatile of the day.

Company shares last traded at $2.06 significantly above the 50 day moving average of $1.10 and which is significantly higher than the 200 day moving average of $1.69. The 50 day moving average went up by +86.84% whereas the 200 day moving average was up $0.37 or +21.54%.

Capricor Therapeutics, Inc. in recent headlines.

Capricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society.

Short Interest

Traders are a little more bearish on the company as evidenced by the rise in short interest. The company realized a rise in short interest from August 15, 2017 to August 31, 2017 of 16.72%. Short shares grew 131,282 over that period. Days to cover increased from 1.0 to 5.0 and the short interest percentage is 0.04% as of August 31. As of the latest earnings report the EPS was $-0.82 and is estimated to be $-0.70 for the current year with 23,496,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.19 and the next full year EPS is anticipated to be $-0.76.

Company Information

Capricor Therapeutics, Inc., launched on January 26, 2007, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. The Company has over four clinical trials aiming to treat cardiovascular diseases in various progressions of the disease state. The Business’s core technology is based on cardiospheres (CSps), which are multi-cell clusters of cardiac-derived cells. The Business’s lead product candidate, the Cardiosphere-Derived Cells (CDCs), are the single cell monolayer product of the CSps. CDCs are small enough that within acceptable dose limits, they can be injected down a coronary artery without damaging the heart muscle. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source)..